Drug Type Small molecule drug |
Synonyms 3-Deazaneplanocin A |
Target |
Action inhibitors |
Mechanism Histone methyltransferases (HMTs) inhibitors, Polycomb repressive complex 2 inhibitors(Polycomb repressive complex 2 inhibitors), SAHH inhibitors(S-adenosyl-L-homocysteine hydrolase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Cancer | Preclinical | United States | 01 Jul 2017 | |
| Melanoma | Preclinical | Japan | 01 Oct 2014 | |
| Esophageal Carcinoma | Preclinical | United States | 15 Apr 2013 | |
| Lung Cancer | Preclinical | United States | 15 Apr 2013 | |
| Multiple Myeloma | Preclinical | Singapore | 15 Apr 2010 |





